CJC-1295: human pharmacology is not an outcome claim

What has been studied in humans

A randomized, placebo-controlled study in healthy adults examined CJC-1295’s pharmacokinetics and pharmacodynamic effects. The reported primary measures were growth hormone and IGF-1 concentrations.

The study found sustained, dose-dependent increases in those laboratory measures. That is meaningful human pharmacology evidence: it shows that the compound affected the measured hormone system under study conditions.

What that does not establish

Hormone changes are not a shortcut to a clinical outcome. The study was not designed to establish improved athletic performance, body composition, injury recovery, sleep, or anti-aging effects.

It also cannot answer every safety question, especially over long periods or in populations unlike the healthy adults included in the trial. A mechanism, biomarker shift, or hormone response should not be written as a guaranteed real-world result.

Canada status

Health Canada’s April 2026 advisory lists CJC-1295 among examples of unauthorized injectable peptide drugs it had seized. The agency advises against buying or using unauthorized injectable drugs and says research-use labelling does not create an exemption from regulatory requirements.

For current authorization information, use Health Canada’s Drug Product Database rather than a seller’s label or a social-media claim.

The useful question

The most accurate short summary is: CJC-1295 has human evidence of GH/IGF-1 pharmacology, while broad lifestyle and performance claims require outcome-specific evidence that this review does not establish.